Founded in 2002, BioAdvance is a venture capital firm based in Radnor, Pennsylvania. The firm seeks to invest in health-tech firms including therapeutics, medical devices, diagnostics, research tools and healthcare IT sectors located in the mid-Atlantic region.
BioAdvance provides funding to startup life sciences companies in Southeastern Pennsylvania through its new $50 million Greenhouse Fund.
Since its first investments, BioAdvance has committed more than $40 million to more than 50 seed-stage companies and 17 pre-seed companies. Their portfolio companies are working to develop products to treat health problems including Alzheimer's disease, cancer, obesity, GI disorders, neurological and respiratory illnesses. BioAdvance was established with $33 million from the Commonwealth of Pennsylvania's share of tobacco settlement.
Their exited investments include Advaxis, Relmada Therapeutics, Novira Therapeutics, NuPathe, HealthQx, Ceptaris Therapeutics, Avid Radiopharmaceuticals, Acuity Pharmaceuticals, Protez Pharmaceuticals and Immune Control.